PL2822947T3 - Sole argininowe agonisty TLR7 - Google Patents
Sole argininowe agonisty TLR7Info
- Publication number
- PL2822947T3 PL2822947T3 PL13708142T PL13708142T PL2822947T3 PL 2822947 T3 PL2822947 T3 PL 2822947T3 PL 13708142 T PL13708142 T PL 13708142T PL 13708142 T PL13708142 T PL 13708142T PL 2822947 T3 PL2822947 T3 PL 2822947T3
- Authority
- PL
- Poland
- Prior art keywords
- tlr7 agonist
- arginine salts
- arginine
- salts
- tlr7
- Prior art date
Links
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608011P | 2012-03-07 | 2012-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2822947T3 true PL2822947T3 (pl) | 2017-01-31 |
Family
ID=47843276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13708142T PL2822947T3 (pl) | 2012-03-07 | 2013-03-07 | Sole argininowe agonisty TLR7 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9320748B2 (https=) |
| EP (1) | EP2822947B1 (https=) |
| JP (1) | JP6325986B2 (https=) |
| CN (1) | CN104203946B (https=) |
| AU (1) | AU2013229466A1 (https=) |
| CA (1) | CA2865759C (https=) |
| CY (1) | CY1118091T1 (https=) |
| DK (1) | DK2822947T3 (https=) |
| ES (1) | ES2597755T3 (https=) |
| HR (1) | HRP20161354T1 (https=) |
| HU (1) | HUE030175T2 (https=) |
| LT (1) | LT2822947T (https=) |
| MX (1) | MX346678B (https=) |
| PL (1) | PL2822947T3 (https=) |
| PT (1) | PT2822947T (https=) |
| RU (1) | RU2014140336A (https=) |
| SI (1) | SI2822947T1 (https=) |
| WO (1) | WO2013131985A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011027222A2 (en) | 2009-09-02 | 2011-03-10 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| AU2011295853A1 (en) | 2010-09-01 | 2013-04-04 | Irm Llc | Adsorption of immunopotentiators to insoluble metal salts |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| MX372965B (es) | 2012-03-08 | 2020-04-01 | Glaxosmithkline Biologicals Sa | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
| CN106103469B (zh) | 2014-03-26 | 2020-11-27 | 葛兰素史密丝克莱恩生物有限公司 | 突变型葡萄球菌抗原 |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| WO2021178306A1 (en) * | 2020-03-01 | 2021-09-10 | Dynavax Technologies Corporation | Coronavirus vaccines comprising a tlr9 agonist |
| US20220280482A1 (en) * | 2021-03-06 | 2022-09-08 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| DE69333110T2 (de) | 1992-03-02 | 2004-05-06 | Chiron S.P.A. | Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| JPH10502366A (ja) | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクター・ピロリ抗原タンパク質調製品およびイムノアッセイ |
| GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| JP2004502415A (ja) | 2000-07-03 | 2004-01-29 | カイロン エセ．ピー．アー． | Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫化 |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| RU2331435C2 (ru) | 2001-12-12 | 2008-08-20 | Чирон Срл. | Иммунизация против chlamydia trachomatis |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| MXPA05013260A (es) | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
| BRPI0508365A (pt) | 2004-03-02 | 2007-07-24 | Chiron Corp | composições imunogênicas para chlamydia pneumoniae |
| SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| RU2007146137A (ru) | 2005-05-12 | 2009-06-27 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Иммуногенные композиции на основе chlamydia trachomatis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| CA2633142A1 (en) | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| BR122016015627A2 (pt) | 2007-10-19 | 2018-10-30 | Novartis Ag | kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica |
| EP3263128A3 (en) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| ES2531115T3 (es) | 2009-06-01 | 2015-03-10 | Novartis Ag | Combinaciones de clados de RrgB neumocócicos |
| JP5867952B2 (ja) * | 2009-06-10 | 2016-02-24 | ノバルティス アーゲー | ベンゾナフチリジン含有ワクチン |
| CN102596240B (zh) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
| JO3257B1 (ar) * | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| WO2011027222A2 (en) * | 2009-09-02 | 2011-03-10 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| AU2011295853A1 (en) | 2010-09-01 | 2013-04-04 | Irm Llc | Adsorption of immunopotentiators to insoluble metal salts |
| EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
| RU2014112343A (ru) * | 2011-09-01 | 2015-10-10 | Новартис Аг | Оставы антигенов staphylococcus aureus, содержащие адъюванты |
-
2013
- 2013-03-07 SI SI201330288A patent/SI2822947T1/sl unknown
- 2013-03-07 PL PL13708142T patent/PL2822947T3/pl unknown
- 2013-03-07 PT PT137081428T patent/PT2822947T/pt unknown
- 2013-03-07 HU HUE13708142A patent/HUE030175T2/en unknown
- 2013-03-07 EP EP13708142.8A patent/EP2822947B1/en active Active
- 2013-03-07 CN CN201380012851.1A patent/CN104203946B/zh active Active
- 2013-03-07 LT LTEP13708142.8T patent/LT2822947T/lt unknown
- 2013-03-07 JP JP2014560367A patent/JP6325986B2/ja active Active
- 2013-03-07 MX MX2014010423A patent/MX346678B/es active IP Right Grant
- 2013-03-07 CA CA2865759A patent/CA2865759C/en active Active
- 2013-03-07 WO PCT/EP2013/054548 patent/WO2013131985A1/en not_active Ceased
- 2013-03-07 RU RU2014140336A patent/RU2014140336A/ru not_active Application Discontinuation
- 2013-03-07 HR HRP20161354TT patent/HRP20161354T1/hr unknown
- 2013-03-07 AU AU2013229466A patent/AU2013229466A1/en not_active Abandoned
- 2013-03-07 DK DK13708142.8T patent/DK2822947T3/en active
- 2013-03-07 ES ES13708142.8T patent/ES2597755T3/es active Active
- 2013-03-07 US US14/381,513 patent/US9320748B2/en active Active
-
2016
- 2016-10-10 CY CY20161101006T patent/CY1118091T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865759C (en) | 2020-07-21 |
| RU2014140336A (ru) | 2016-04-27 |
| EP2822947B1 (en) | 2016-08-03 |
| CN104203946A (zh) | 2014-12-10 |
| HUE030175T2 (en) | 2017-04-28 |
| WO2013131985A1 (en) | 2013-09-12 |
| HRP20161354T1 (hr) | 2016-12-02 |
| SI2822947T1 (sl) | 2016-10-28 |
| JP2015511957A (ja) | 2015-04-23 |
| JP6325986B2 (ja) | 2018-05-16 |
| CN104203946B (zh) | 2017-03-22 |
| MX2014010423A (es) | 2014-09-22 |
| DK2822947T3 (en) | 2016-09-19 |
| US9320748B2 (en) | 2016-04-26 |
| MX346678B (es) | 2017-03-29 |
| ES2597755T3 (es) | 2017-01-20 |
| EP2822947A1 (en) | 2015-01-14 |
| CA2865759A1 (en) | 2013-09-12 |
| US20150125475A1 (en) | 2015-05-07 |
| CY1118091T1 (el) | 2017-06-28 |
| AU2013229466A1 (en) | 2014-09-04 |
| LT2822947T (lt) | 2016-10-10 |
| PT2822947T (pt) | 2016-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401884B (en) | New dihydroquinoline-2-one derivatives | |
| LT2822947T (lt) | Tlr7 agonisto arginino druskos | |
| EP2970081A4 (en) | SALTS OF TREPROSTINIL | |
| GB201304499D0 (en) | Carcainium Salts | |
| SG11201401937YA (en) | New aryl-quinoline derivatives | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| ZA201308401B (en) | Substituted benzamide derivatives | |
| ZA201409327B (en) | Solid forms of a pyrido-pyrimidinium inner salt | |
| IL231269A0 (en) | Preparations for the treatment of HIV | |
| ZA201406238B (en) | Crystalline form of a succinate salt | |
| ZA201307229B (en) | Prodrugs of d-isoglutamyl-[d/l]- tryprophan | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| IL237382A0 (en) | Salts of a benzothiazolone compound as beta-2 adrenergic receptor agonists | |
| PL2760822T3 (pl) | Sole desfezoterodyny | |
| ZA201308872B (en) | Use of a dinitromethane salt | |
| GB201100332D0 (en) | Monty Izofit | |
| ZA201205358B (en) | Use of a salt of bistetrazolylamine | |
| GB201106819D0 (en) | Novel salts | |
| GB201209895D0 (en) | Use of a composition | |
| GB201219868D0 (en) | Facilitating completion of a form | |
| GB201204590D0 (en) | Prodrugs of thiazolamine compounds |